Patents by Inventor Carl F. Ware

Carl F. Ware has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10220081
    Abstract: The invention provides HVEM cis complexes which include, for example, HVEM/BTLA, HVEM/CD160 and HVEM/gD cis complexes. The invention provides ligands and agents that bind to HVEM cis complexes, such as antibodies. The invention further provides methods of use of the HVEM cis complexes, and the ligands and agents (e.g., LIGHT polypeptide sequence) that bind to the HVEM cis complexes.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: March 5, 2019
    Assignee: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventors: Carl F. Ware, Timothy C. Cheung, Marcos Steinberg
  • Patent number: 10106619
    Abstract: The invention relates to compositions and methods that employ OX40 (CD134), a TNFR superfamily protein, agonists. The invention includes among other things administering an OX40 agonist alone or in combination with a viral antigen, or live or attenuated virus, to treat a viral infection, or for vaccination or immunization.
    Type: Grant
    Filed: October 4, 2007
    Date of Patent: October 23, 2018
    Assignee: La Jolla Institute for Allergy and Immunology
    Inventors: Michael Croft, Shahram Salek-Ardakani, Magdalini Moutaftsi, Alessandro Sette, Carl F. Ware
  • Publication number: 20180170999
    Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.
    Type: Application
    Filed: June 29, 2016
    Publication date: June 21, 2018
    Inventors: Carl F. Ware, John Sedy, Tigran Aivazian, Brian Miller, Natasha K. Crellin
  • Publication number: 20180155426
    Abstract: The present invention relates to the seminal discovery that BTLA agonist antibodies modulate the immune system. Specifically, the present invention provides antibodies which bind BTLA in the activated state enhancing BTLA signaling. The present invention further provides methods of treating immune and inflammatory diseases and disorders with a BTLA agonist antibody.
    Type: Application
    Filed: April 29, 2016
    Publication date: June 7, 2018
    Inventors: Carl F. WARE, John SEDY, Paula NORRIS
  • Patent number: 9982023
    Abstract: Ligand-specific HVEM variants, compositions comprising such variants, and methods of treating inflammatory diseases comprising administering such variants, are provided.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: May 29, 2018
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Carl F. Ware, John Sedy
  • Patent number: 9771419
    Abstract: Provided herein are antibodies that immunospecifically bind to an hLIGHT polypeptide; isolated nucleic acids encoding the antibodies; vectors and host cells comprising nucleic acids encoding the antibodies; methods of making the antibodies; and a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject the antibodies. In preferred embodiments, the anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: September 26, 2017
    Assignees: KYOWA HAKKO KIRIN CO., LIMITED, LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventors: Steven W. Granger, Shinichiro Kato, Carl F. Ware
  • Patent number: 9700606
    Abstract: The invention provides HVEM cis complexes which include, for example, HVEM/BTLA, HVEM/CD160 and HVEM/gD cis complexes. The invention provides ligands and agents that bind to HVEM cis complexes, such as antibodies. The invention further provides methods of use of the HVEM cis complexes, and the ligands and agents (e.g., antibodies) that bind to the HVEM cis complexes.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: July 11, 2017
    Assignee: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventors: Carl F. Ware, Timothy C. Cheung, Marcos W. Steinberg
  • Patent number: 9694058
    Abstract: The tumor-necrosis factor superfamily member LIGHT (p30; TNFSF-14) is a cytokine for inducing immune responses against tumors. A novel biochemical approach is used to decorate the surface of tumor cells with LIGHT. LIGHT decorated cells can be used to vaccinate and induce effective, sustained immunity against cells expressing neo or pathogen associated antigens. Variants of LIGHT are described that enhance binding to cellular receptors (e.g., LT beta receptor) and decrease regulation by inhibitors (e.g., Decoy Receptor 3) increasing ability to stimulate immunity.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: July 4, 2017
    Assignee: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventors: Carl F Ware, Timothy C. Cheung, Theresia A. Banks
  • Publication number: 20160194403
    Abstract: The present invention relate to the discovery that BTLA, IL-7 and ROR?t modulate the activity and expression of ??T cells. Specifically, the present invention provides methods of modulating ??T cell homeostasis and function by regulating expression of BTLA. The present invention further provides agents which modulate the activity and expression of BTLA, RORyt and IL-7 and methods for screening of such agents. The present invention also provides methods for treating autoimmune or inflammatory diseases using modulators of BTLA, RORyt and IL-7.
    Type: Application
    Filed: September 4, 2014
    Publication date: July 7, 2016
    Inventors: Carl F. WARE, John R. SEDY
  • Publication number: 20150337046
    Abstract: Provided herein are antibodies that immunospecifically bind to an hLIGHT polypeptide; isolated nucleic acids encoding the antibodies; vectors and host cells comprising nucleic acids encoding the antibodies; methods of making the antibodies; and a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject the antibodies. In preferred embodiments, the anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental.
    Type: Application
    Filed: February 2, 2015
    Publication date: November 26, 2015
    Inventors: Steven W. Granger, Shinichiro Kato, Carl F. Ware
  • Publication number: 20150266964
    Abstract: This disclosure describes methods that generally include administering to an immune compromised subject an amount of a lymphotoxin ? receptor (LT?R) agonist effective to increase immune function in the subject compared to a suitable control immune compromised subject. In some cases, the method can result decreasing the period of immune deficiency in the subject compared to a suitable control immune compromised subject.
    Type: Application
    Filed: October 4, 2013
    Publication date: September 24, 2015
    Inventors: Bruce R. Blazar, Heather E. Stefanski, Carl F. Ware
  • Patent number: 8974787
    Abstract: Provided herein are antibodies that immunospecifically bind to an hLIGHT polypeptide; isolated nucleic acids encoding the antibodies; vectors and host cells comprising nucleic acids encoding the antibodies; methods of making the antibodies; and a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject the antibodies. In preferred embodiments, the anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: March 10, 2015
    Assignees: Kyowa Hakko Kirin Co., Limited, La Jolla Institute for Allergy and Immunology
    Inventors: Steven W. Granger, Shinichiro Kato, Carl F. Ware
  • Publication number: 20140220051
    Abstract: The invention provides HVEM cis complexes which include, for example, HVEM/BTLA, HVEM/CD160 and HVEM/gD cis complexes. The invention provides ligands and agents that bind to HVEM cis complexes, such as antibodies. The invention further provides methods of use of the HVEM cis complexes, and the ligands and agents (e.g., LIGHT polypeptide sequence) that bind to the HVEM cis complexes.
    Type: Application
    Filed: February 7, 2014
    Publication date: August 7, 2014
    Inventors: CARL F. WARE, TIMOTHY C. CHEUNG, MARCOS STEINBERG
  • Publication number: 20130230536
    Abstract: Provided herein are antibodies that immunospecifically bind to an hLIGHT polypeptide; isolated nucleic acids encoding the antibodies; vectors and host cells comprising nucleic acids encoding the antibodies; methods of making the antibodies; and a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject the antibodies. In preferred embodiments, the anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental.
    Type: Application
    Filed: May 8, 2013
    Publication date: September 5, 2013
    Applicants: La Jolla Institute for Allergy and Immunology, Kyowa Hakko Kirin Co., Limited
    Inventors: Steven W. Granger, Shinichiro Kato, Carl F. Ware
  • Patent number: 8461307
    Abstract: Provided herein are antibodies that immunospecifically bind to an hLIGHT polypeptide; isolated nucleic acids encoding the antibodies; vectors and host cells comprising nucleic acids encoding the antibodies; methods of making the antibodies; and a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject the antibodies. In preferred embodiments, the anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: June 11, 2013
    Assignees: Kyowa Hakko Kirin Co., Limited, La Jolla Institute for Allergy and Immunology
    Inventors: Steven W. Granger, Shinichiro Kato, Carl F. Ware
  • Patent number: 8349320
    Abstract: Herpesvirus entry mediator (HVEM) is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and acts as a molecular switch that modulates T cell activation by propagating positive signals from the TNF related ligand, LIGHT (p30, TNFSF14), or inhibitory signals through the immunoglobulin superfamily member, B and T lymphocyte attenuator (BTLA). A novel binding site for BTLA is disclosed, located in cysteine-rich domain-1 of HVEM. BTLA binding site on HVEM overlaps with the binding site for the Herpes Simplex virus-1 envelope glycoprotein D (gD), but is distinct from where LIGHT binds, yet gD inhibits the binding of both ligands. A BTLA activating protein present in human cytomegalovirus is identified as UL144. UL144 binds BTLA, but not LIGHT, and inhibits T cell proliferation.
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: January 8, 2013
    Assignee: La Jolla Institute for Allergy and Immunology
    Inventors: Carl F. Ware, Carl De Trez, Michael Croft, Timothy C. Cheung, Ian R. Humphreys, Karen G. Potter, Christopher A. Benedict, Mitchell Kronenberg, Marcos W. Steinberg
  • Publication number: 20120251505
    Abstract: The invention provides human lymphoid tissue inducer (LTi) cells, methods of producing human lymphoid tissue inducer (LTi) cells, and methods of using human lymphoid tissue inducer (LTi) cells. Such methods include treatment of a subject that would benefit from human lymphoid tissue inducer (LTi) cells, for example, an immunocompromised or immunosuppressed subject.
    Type: Application
    Filed: September 3, 2010
    Publication date: October 4, 2012
    Applicant: La Jolla Institute for Allergy and Immunology
    Inventors: Carl F. Ware, Vasileios Bekiaris
  • Publication number: 20120141465
    Abstract: The invention relates to compositions and methods that employ OX40 (CD134), a TNFR superfamily protein, agonists. The invention includes among other things administering an OX40 agonist alone or in combination with a viral antigen, or live or attenuated virus, to treat a viral infection, or for vaccination or immunization.
    Type: Application
    Filed: October 4, 2007
    Publication date: June 7, 2012
    Applicant: La Jolla Institute for Allergy and Immunology
    Inventors: MICHAEL CROFT, Shahram Salek-Ardakani, Magdalini Moutaftsi, Alessandro Sette, Carl F. Ware
  • Patent number: 8153123
    Abstract: The present invention provides methods for restoring and increasing dendritic cell populations in a subject by modulation of the lymphotoxin-? receptor (LT?R) via LT?R agonists. The invention also provides methods for screening for agents capable of restoring or increasing dendritic cell populations. The invention further provides a method for the treatment of immunodeficiency by administration of an LT?R agonist.
    Type: Grant
    Filed: June 11, 2009
    Date of Patent: April 10, 2012
    Assignee: La Jolla Institute for Allergy and Immunology
    Inventors: Carl F. Ware, Carl De Trez
  • Publication number: 20120076798
    Abstract: Provided herein are antibodies that immunospecifically bind to an hLIGHT polypeptide; isolated nucleic acids encoding the antibodies; vectors and host cells comprising nucleic acids encoding the antibodies; methods of making the antibodies; and a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject the antibodies. In preferred embodiments, the anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental.
    Type: Application
    Filed: September 22, 2011
    Publication date: March 29, 2012
    Applicants: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY, KYOWA HAKKO KIRIN CO., LIMITED
    Inventors: Steven W. Granger, Shinichiro Kato, Carl F. Ware